A Danish research team has identified a previously unknown bacteriophage hiding inside Bacteroides fragilis, a common gut bacterium, and found it more often in people with colorectal cancer. The study analyzed stool samples from several regions and reports roughly double the prevalence of this viral trace in cancer patients. This finding opens new questions about how the microbiome and its viruses might influence cancer risk and screening.
Scientists long noticed Bacteroides fragilis appears more frequently in people with colorectal cancer, yet the bacterium is also common in healthy guts. That paradox prompted researchers to dig into genetic differences within the bacteria rather than treat all Bacteroides fragilis strains the same. What they found was an unexpected viral hitchhiker tucked inside some bacterial genomes.
“These findings highlight the importance of the microorganisms in the gut and their relation to our health,” Dr. Flemming Damgaard, PhD, of the Department of Clinical Microbiology at Odense University Hospital and the University of Southern Denmark, told Fox News Digital. The team discovered a bacteriophage, a virus that infects bacteria rather than human cells, that had not been documented before.
When researchers looked at stool samples from 877 people across Europe, the United States and Asia, they found colorectal cancer patients were about twice as likely to carry traces of that virus compared with people without cancer. The association is statistically strong, but association is not causation, and the researchers are careful not to claim the virus causes cancer. Still, the pattern was striking enough to push follow-up work into lab and animal models.
“We were very surprised to find a whole virus inside the bacteria from the colorectal cancer patients,” Damgaard said. The team is now running experiments to see whether the bacteriophage changes Bacteroides fragilis behavior in ways that might promote tumor development or inflammation in the colon.
“The major limitation is that we still don’t know why the virus is linked to colorectal cancer,” said co-author Ulrik Stenz Justesen. “But we are already continuing our research.” The next steps include controlled laboratory studies and animal experiments designed to test mechanisms rather than mere presence or absence of viral traces.
Microbes far outnumber human cells in our bodies, and the gut microbiome has been tied to digestion, immunity and drug response. “Our understanding of [microbial cells] is still in its infancy,” Damgaard said. That leaves plenty of room for discoveries that shift how we think about disease causes and prevention.
Colorectal cancer remains a leading cause of cancer deaths globally, and its incidence has drawn broad attention after several high-profile cases. Names reported in public discourse have included James Van Der Beek, Catherine O’Hara, Kirstie Alley, Pelé and Chadwick Boseman, which has sharpened public awareness that colorectal cancer can affect people across age groups.
Typical screening today relies on stool tests for hidden blood and colonoscopy when indicated, and clinicians use risk factors like age, family history and lifestyle to guide screening schedules. The idea of adding microbial or viral markers to stool-based tests is attractive because it might identify risk patterns missed by current screening or provide earlier biological clues.
Researchers point to cervical cancer as an example where identifying a viral cause transformed prevention; after HPV was linked to cervical cancer, vaccines dramatically reduced new cases. It is too early to claim a parallel for colorectal cancer, but the researchers say a confirmed viral role could pave the way for novel prevention strategies down the line.
For now, this study offers a new lead rather than an answer. The group emphasizes caution and the need for further validation in different populations and experimental systems before translating findings into clinical tests or interventions. The discovery underscores the complexity of the gut ecosystem and the potential for tiny viral players to matter in big ways.
Because the current work shows correlation rather than cause and effect, scientists are planning more targeted experiments to test whether the bacteriophage can alter bacterial behavior in ways that promote tumor growth. If such mechanisms are found, that could change how researchers hunt for preventable pathways and design future screening tools.
